Revised 17 September 2026 · v1.0.0 · what changed

This blog's own reporting on India's ethanol-blending mandate has already made one argument: E20 blending frees refinery capacity that used to make petrol, and refiners are redirecting a real, capital-backed share of it into petrochemicals — but not yet into the naphtha- and benzene-derived chemistry that feeds paracetamol and ibuprofen manufacturing, a chain still 43% dependent on China by import value. Bilateral trade data adds a harder edge to that argument: some of the freed capacity isn't waiting for a KSM plant to be built. It is being exported, raw, to China — the same country India is trying to depend on less for the finished drug.

1. The naphtha number

India's exports of light and full-range naphtha (HS 27101221 and 27101229) to China ran flat-to-declining for two years, then reversed sharply:

The reversal lands in exactly the fiscal year this blog's own reporting confirms E20 blending took hold nationwide across India's petrol pool. That is a specific, dated coincidence, not a vague correlation — and it does not, on its own, prove the freed capacity and the export surge are the same barrels. What it does establish is a fact the ethanol-and-petrochemicals story didn't have before: naphtha leaving India for China is rising exactly when naphtha available for anything else is rising too.

2. It isn't only naphtha

Naphtha is the largest line, but not the only one. Benzene — the aromatic ring at the root of both paracetamol's and ibuprofen's synthesis routes, per this blog's own earlier breakdown of the chemistry — has risen every single year since FY2022-23, without exception:

Four straight years of growth, cumulative +346% since FY2022-23. Benzene is not naphtha's byproduct in the way industrial-fuel-grade naphtha is a refining leftover — a refiner has to run a reformer or cracker specifically to make it, the same unit that would also supply a KSM plant making isobutylbenzene (ibuprofen's precursor) or nitrobenzene (paracetamol's, via para-aminophenol). The molecule reaching China is not a different one from the molecule pharma manufacturing needs; it is the same molecule, sent to a different buyer.

3. The one molecule with a name, and a complication

One HS line in this dataset maps onto a molecule this blog has already named directly: isobutylbenzene (IBB, HS 29029050), the actual key starting material for ibuprofen by the BHC/Hoechst catalytic route described in this blog's earlier chemistry breakdown. Benzene is alkylated with propylene to make it; IBB is oxidised and carbonylated to make ibuprofen itself. Finding India exporting IBB to China while importing 80.73% of its finished ibuprofen from the same country would be as close to a one-to-one, name-the-molecule irony as bilateral trade data gets.

The data delivers half of that irony, not the whole thing:

Put plainly: the "give away the feedstock, buy back the drug" pattern is real for naphtha and benzene, where exports are rising while the finished-drug import bill stays high. It is not what is happening for IBB specifically, where exports are falling and the finished-drug dependence is improving. Both facts belong in the same piece, because a reader checking one obvious candidate molecule and finding it doesn't fit the pattern is exactly the kind of check this blog's own research-completion discipline exists to force.

4. How big a share of the export relationship is this

Naphtha, benzene and isobutylbenzene together came to roughly $2.65bn of India's $19.47bn in total exports to China in FY2025-26 — about 13.6% of everything India sold that country, in three product lines that are, at most, one refining step removed from a barrel of crude. That is a meaningful share of a bilateral trade relationship already running an $112.1bn deficit against India (imports $131.6bn, exports $19.5bn, FY2025-26) to be concentrated in feedstock rather than finished goods — not proof of anything sinister, but a specific, quantified answer to what, exactly, has to happen for India's export mix to China to look more like a value-added economy's and less like a quarry's.

5. Why the domestic chain doesn't just absorb this instead

This blog's own reporting on the ethanol-freed-capacity question already found three reasons the naphtha and benzene reaching the ground today aren't routed to a domestic KSM plant instead: India still imports chemical-grade naphtha because domestic naphtha commonly isn't refined to cracker purity; the Bulk Drugs PLI (₹6,940cr outlay) localised 28 fermentation-route molecules and named none of the petrochemical-route ones this piece is about; and China's own para-aminophenol capacity alone runs at roughly three times India's total demand, built by producers operating at scale for two decades — a pricing wall a new Indian KSM plant would face from day one. Naphtha and benzene heading to China instead of a domestic cracker-to-KSM chain is not a separate, fourth mystery. It is what the same three constraints predict once there is a buyer next door already paying for the raw material.

6. What would actually close the loop

Nothing about the underlying feedstock economics changes on its own. The petrochemical capacity India is building at Paradip, Ramayapatnam, Bina and Barmer (this blog's own tracking of the build-out) is real, and it will keep producing more naphtha, benzene and olefins whether or not any of it reaches pharma. Closing the loop this piece describes needs the same thing this blog's ethanol-and-petrochemicals reporting already concluded: an import-substitution scheme that names paracetamol's and ibuprofen's specific synthetic-route KSMs as targets, the way the Bulk Drugs PLI already named fermentation-route molecules — not a naphtha-availability problem, since naphtha is demonstrably available; a routing and market-design problem, since the naphtha and benzene already have a paying buyer that isn't a domestic KSM plant.

Sources: DGCI&S TradeStat, Export → Country-wise-all-commodities reports for China (four files covering FY2022-23 through FY2025-26), HS 27101221 (light naphtha), 27101229 (full-range naphtha), 29022000 (benzene) and 29029050 (isobutylbenzene); each fiscal year's bilateral total (used in Section 4) is read from the report's own "Total" row, not re-summed from individual HS lines — an earlier read of this same data doubled every total by summing that row a second time alongside the commodity rows it already covers, caught by sanity-checking against the published $101.7bn FY2023-24 India-China import figure before use. Nitrobenzene/para-aminophenol figures (Section 2) are read the same way and are genuinely near-zero across all four years, not an artifact of the search terms used. This blog's own "Ethanol Freed Up Refinery Capacity for Petrochemicals," "The Barrel Really Is Shifting: India's Refiners Quantify the Petrochemical Pivot," "Financing the Fuel-to-Chemicals Pivot" and "Five Years and ₹25,000 Crore Later, China Still Supplies Three-Quarters of India's Drug-Making Ingredients" for the E20-timing claim, the petrochemical build-out figures, the Bulk Drugs PLI scope, and the paracetamol/ibuprofen China-dependency and chemistry-route figures reused directly rather than re-derived here. Nothing in this piece is investment or policy advice.

Related on this blog

See also: Ethanol Freed Up Refinery Capacity for Petrochemicals. The Pharma Chain Hasn't Seen Much of It Yet. · The Barrel Really Is Shifting: India's Refiners Quantify the Petrochemical Pivot · Financing the Fuel-to-Chemicals Pivot · India Cannot Sell “China-Free” Medicine While Importing 43% of What's In It · Five Years and ₹25,000 Crore Later, China Still Supplies Three-Quarters of India's Drug-Making Ingredients.

About this article: Researched, written and edited by Umashankar Triplicane Dwarakanathan, with AI research assistance; every figure is meant to trace to the primary source cited. See the Editorial Policy for how sourcing, AI use and corrections work.